XML 59 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Earnings (Loss) Per Common Share
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Net Earnings (Loss) Per Common Share
Net Loss Per Common Share

The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated.
(In thousands except per share data)
For the Three Months Ended June 30,
 
For the Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Basic
 
 
 
 
 
 
 
Average common shares outstanding
33,169

 
32,833

 
33,040

 
32,654

 
 
 
 
 
 
 
 
Net loss
$
(16,543
)
 
$
(23,508
)
 
$
(30,651
)
 
$
(40,288
)
 
 
 
 
 
 
 
 
Net loss per common share
$
(0.50
)
 
$
(0.72
)
 
$
(0.93
)
 
$
(1.23
)
 
 
 
 
 
 
 
 
Diluted
 
 
 
 
 
 
 
Average common shares outstanding
33,169

 
32,833

 
33,040

 
32,654

Stock options and awards
827

 
360

 
827

 
293

Average common shares assuming dilution
33,996

 
33,193

 
33,867

 
32,947

 
 
 
 
 
 
 
 
Net loss
$
(16,543
)
 
$
(23,508
)
 
$
(30,651
)
 
$
(40,288
)
 
 
 
 
 
 
 
 
Net loss per common share *
$
(0.50
)
 
$
(0.72
)
 
$
(0.93
)
 
$
(1.23
)

________
* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

At June 30, 2018, 329,315 shares associated with stock options were excluded from the average common shares assuming dilution for both the three and six months ended June 30, 2018 as they were anti-dilutive. At June 30, 2018, the majority of the anti-dilutive shares were granted at an exercise price of $25.79, which was higher than the average fair market value price of $18.09 and $17.87 for the three and six months ended June 30, 2018, respectively.

At June 30, 2017, 1,353,144 and 1,629,336 shares associated with stock options were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2017, respectively, as they were anti-dilutive. At June 30, 2017, the majority of the anti-dilutive shares were granted at an exercise price of $25.79, which was higher than the average fair market value price of $13.14 and $12.57 for the three and six months ended June 30, 2017, respectively.











For both the three and months ended June 30, 2018 and June 30, 2017, respectively, no shares were included in the common shares assuming dilution related to the company's issued warrants as the average market price of the company stock for these periods did not exceed the strike price of the warrants.